Marc THIBONNIER
Company: AptamiR Therapeutics
Job title: Founder & President
Seminars:
Active Cellular Targeting miRNA Oligonucleotide Therapeutics (ONTs) to Treat Metabolic Pandemics 11:00 am
Discovery and validation of miR-22-3p as an excellent metabolic miRNA In silico, in vitro and in vivo validation of miR-22-3p antagomirs to treat obesity, MAFLD and related cardiometabolic disorders Current preclinical validation of Generation 2.5 miR-22-3p antagomirs for enhanced active targeted delivery of a greatly reduced therapeutic dose with an extended intracellular Mean Residence TimeRead more
day: Seminar A- AM tracks